Iba T, Yagi Y, Kidokoro A, Fukunaga M, Momose F
Dept. of Surgery, Juntendo Urayasu Hospital, Juntendo University School of Medicine.
Gan To Kagaku Ryoho. 1995 Jan;22(1):83-6.
Fourteen patients with recurrent breast cancer were treated with a combination of mitoxantrone (10 mg/m2 iv, day 1), vincristine (1 mg/m2 iv, day 1) and prednisolone (30 mg/day day 1-7). Cycles were repeated every 4 weeks and all patients received more than 3 cycles. The objective response rate was 70.0% (7 of 10). In two patients, the treatment has been continued now for more than one year. In these 2 patients, the duration of response is more than 40 weeks. The toxicity was primarily myelosuppression. Five of 14 patients (35.7%) had leukopenia of Grade 3 and 4. These patients received G-CSF therapy and recovered well from leukopenia. Nausea and vomiting were well tolerated, probably by prednisolone. This regimen was especially superior in the maintenance of quality of life because hair loss was much less compared to CAF (cyclophosphamide, ADM, 5-fluorouracil) treatment. In conclusion, MVP treatment is highly effective and safe for the treatment of recurrent breast cancer.
14例复发性乳腺癌患者接受了米托蒽醌（10mg/m²静脉注射，第1天）、长春新碱（1mg/m²静脉注射，第1天）和泼尼松龙（30mg/天，第1 - 7天）联合治疗。每4周重复1个周期，所有患者接受了3个以上周期的治疗。客观缓解率为70.0%（10例中的7例）。有2例患者目前治疗已持续1年以上。在这2例患者中，缓解持续时间超过40周。毒性主要为骨髓抑制。14例患者中有5例（35.7%）出现3级和4级白细胞减少。这些患者接受了粒细胞集落刺激因子治疗，白细胞减少恢复良好。恶心和呕吐耐受性良好，可能得益于泼尼松龙。与CAF（环磷酰胺、多柔比星、5-氟尿嘧啶）治疗相比，该方案在维持生活质量方面尤为优越，因为脱发要少得多。总之，MVP方案治疗复发性乳腺癌高效且安全。
